Why Are Bellerophon Shares Jumping Today?
The FDA has accepted Bellerophon Therapeutics Inc’s (NASDAQ:BLPH) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3…
Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 REBUILD Study Of INOpulse For Treatment Of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint
Independent Data Monitoring Committee agreed
Bellerophon Therapeutics: Q2 Earnings Insights
Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Bellerophon Therapeutics reported an EPS of $-0.43.
Bellerophon Therapeutics Q2 EPS $(0.43) Down From $(0.36) YoY
Bellerophon Therapeutics (NASDAQ:BLPH) reported quarterly losses of $(0.43) per share. This is a 19.44 percent decrease over losses of $(0.36) per share from the same period last year.
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Why Is NeuroSense Therapeutics Surging by 70%? 46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: Bellerophon Therapeutics Q1 Earnings
Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.